anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The activity of ROXICODONE® (oxycodone hydrochloride) tablets is primarily due to the parent drug oxycodone. ROXICODONE® tablets are designed to provide immediate release of oxycodone.

Absorption: About 60% to 87% of an oral dose of oxycodone reaches the systemic circulation in comparison to a parenteral dose. This high oral bioavailability (compared to other oral opioids) is due to lower pre-systemic and/or first-pass metabolism of oxycodone. The relative oral bioavailability of ROXICODONE® 15 mg and 30 mg tablets, compared to the 5 mg ROXICODONE® tablets, is 96% and 101% respectively. ROXICODONE® 15 mg tablets and 30 mg tablets are bioequivalent to the 5 mg ROXICODONE® tablet (see Table 1 for pharmacokinetic parameters). Dose proportionality of oxycodone has been established using the ROXICODONE® 5 mg tablets at doses of 5 mg, 15 mg (three 5 mg tablets) and 30 mg (six 5 mg tablets) based on extent of absorption (AUC) (see Figure 1). It takes approximately 18 to 24 hours to reach steady-state plasma concentrations of oxycodone with ROXICODONE®.

Figure 1 - Roxicodone Dose-Proportionality Study 5 mg, 15 mg and 30 mg (single-dose)

Food Effect: A single-dose food effect study was conducted in normal volunteers using the 5 mg/5 mL solution. The concurrent intake of a high fat meal was shown to enhance the extent (27% increase in AUC), but not the rate of oxycodone absorption from the oral solution (see Table 1). In addition, food caused a delay in Tmax (1.25 to 2.54 hour). Similar effects of food are expected with the 15 mg and 30 mg tablets.

Distribution: Following intravenous administration, the volume of distribution (Vss) for oxycodone was 2.6 L/kg. Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%. Oxycodone has been found in breast milk (see PRECAUTIONS-Nursing Mothers).

Metabolism: Oxycodone hydrochloride is extensively metabolized to noroxycodone, oxymorphone, and their glucuronides. The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone. Oxymorphone is present in the plasma only in low concentrations. The analgesic activity profile of other metabolites is not known at present.

The formation of oxymorphone, but not noroxycodone, is mediated by CYP2D6 and as such its formation can, in theory, be affected by other drugs (see PRECAUTIONS-Drug Interactions). 

Elimination: Oxycodone and its metabolites are excreted primarily via the kidney. The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone ≤ 14%; both free and conjugated noroxycodone have been found in the urine but not quantified. The total plasma clearance was 0.8 L/min for adults. Apparent elimination half-life of oxycodone following the administration of ROXICODONE® was 3.5 to 4 hours.
A method and system for generation and validation of clinical reports with built-in automated measurement and decision support is provided. XML templates may be used for ensuring report data quality. The template data may include static, dynamic, calculated data, and others. The validation method may be based on formal logical constraint specifications. The constraint descriptions may include data types, cardinality, order, co-occurrence, Boolean logic, read-only data, regular expression patterns, etc. The method can be used to validate collected data on-the-fly based on constraint specifications without human interaction.
NEW MATERIAL:A compound of formula I (R is lower alkyl; n is 1, 2; A us ligand of formula II). EXAMPLE:cis-Glycolato-N-(2-aminopropyl)cyclopentylamine platinum (II). USE:Antitumor agent. PREPARATION:Silver sulfate is allowed to react with a halogenoplatinum complex of formula III (X is Cl, Br, I) to give a compound of formula IV. Then, barium hydroxide is allowed to act on the product to form a compound of formula V, which is further allowed to react with glycolic acid to give the compound of formula I. The compounds of formula IV, and V are directly subjected to the reactions without isolation.
An unlimited number of participants will be accepted into a Baseline registry. From the Baseline registry, approximately 10,000 participants will be selected for the Baseline Study. Participant enrollment for the Baseline Study will be stratified by age, sex and risk factors and will aim to reflect the race and ethnicity distribution within the U.S.. The population includes a broad range of participants across the health spectrum, including exceptionally healthy participants, participants at risk of disease, and participants with current disease. The study population will be enriched for participants with an elevated risk of primary cardiovascular disease, lung cancer, and/or breast/ovarian cancers.
Patients will receive a 20 minute hand massage by a trained nurse in addition to the standard ICU care. Before administering the massage, a favorable environment will be created that promotes calmness such as dampening the light, reducing the alarm intensity, closing the curtains and the door and posting the notice "do not disturb", and a comfortable positioning of the patient will be ensured. The interventionist will hold each hand for 5-10 seconds, and apply 5-10 ml of unscented hypoallergenic cream to both hands and wrists. Then, she will perform massage using moderate pressure, and the stroking and kneading techniques during ten minutes on the palm and back of each hand.
The invention relates to a 2-amino-1-(4-nitrobenzophenone)-1-ethanol metalloproteinase inhibitor as well as a preparation and application thereof. The 2-amino-1-(4-nitrobenzophenone)-1-ethanol metalloproteinase inhibitor is a compound with the following general formula (1). Dipeptide-like or kyrine-type compounds of different series can enhance the appetency and metabolization stability of a compound and an enzyme or a receptor and conforms to the basic requirement on inhibitor structures. The invention designs and synthesizes a group of aminopeptidase N inhibitors with totally new structures. A vitro test shows that the inhibitors have no cytotoxin activity, and four compounds which exhibit remarkable vitro inhibitory activity are close to positive control medicine bestatin and can be used as candidate anticancer medicines. The invention also relates to a pharmaceutical composition of a peptide-like compound with a structure indicated by formula (I), and also relates to the pharmacy usage of the pharmaceutical composition.
1,125,210. Medicinal virus preparations. AMERICAN HOME PRODUCTS CORP. 16 Aug., 1967 [31 Aug., 1966], No. 37599/67. Heading A5B. [Also in Division C6] A dosage form for the immunization of the intestinal tract with live virus preparations comprises; an inner pressed tablet containing at least one pharmaceutically acceptable solid excipient and a live virus capable of infecting the intestinal tract; an intermediate pressed layer, containing at least one pharmaceutically-acceptable solid excipient, completely encasing the inner pressed tablet and providing a shell which per se has a minimum wall thickness of 0.03 inch; and an outer enteric coating material completely covering the intermediate pressed layer. According to an example, lyophilised solids obtained by the freeze-drying of filtered adonovirus type IV in the presence of skim milk, gelatin and human serum albumin, were tabletted with a mixture of lactose, microcrystalline cellulose and magnesium stearate. The tablets were then press coated with a similar mixture and to the press-coated tablets there was applied an enteric coating solution prepared by admixing cellulose acetate hydrogen phthalate and castor oil with acetone and absolute alcohol. The inner pant or core may be either a compressed tablet of lyophilised material or a compressed tablet of solid material containing adsorbed liquid virus e.g. virus-containing fluids adsorbed on sugar or resins. Other viruses which can be incorporated in Ithe press-coated tablets are influenza, parainfluenza, rhinoviruses and other viruses whose primary infection site is not the intestine.
The development of a potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions have been reported with SNRIs and SSRIs alone, including Savella, but particularly with concomitant use of serotonergic drugs (including triptans), with drugs which impair metabolism of serotonin (including MAOIs) or with antipsychotics or other dopamine antagonists. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea) [see Drug Interactions (7)]. Serotonin syndrome, in its most severe form, can resemble neuroleptic malignant syndrome, which includes hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs, and mental status changes. Patients should be monitored for the emergence of serotonin syndrome or NMS-like signs and symptoms. The concomitant use of Savella with MAOIs is contraindicated [see Contraindications (4.1)].

If concomitant treatment of Savella with a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Drug Interactions (7)].

The concomitant use of Savella with serotonin precursors (such as tryptophan) is not recommended [see Drug Interactions (7)]. Treatment with Savella and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately if the above events occur, and supportive symptomatic treatment should be initiated.
PURPOSE:To obtain a hair production and growth agent, containing an extract of Aconitum chinense Sieb. and having high safety without any skin irritancy and allergy. CONSTITUTION:The objective substance obtained by extracting a root, stem or leaf of Aconitum chinense Sieb. which is a ranunculaceous plant with water or an alcohol (e.g. methanol) at ambient temperature or by heating, using the resultant extract in an intact liquid state or concentrating and evaporating the extract to dryness, blending the extract with an additive such as a carrier, emulsifying agent, suspending agent or aromatic agent normally used in cosmetics, medicines, etc., and preparing a formulation according to a conventional method. The aforementioned agent is prepared in the form of a hair tonic, hair lotion, hair shampoo, etc., or a composition for ointments and applied.
BACKGROUND: In adults with serious respiratory illness, breathlessness is prevalent and associated with reduced health-related quality of life. The aim of this review was to assess the impact of breathing techniques on breathlessness in adults with serious respiratory illness.
METHODS: Electronic databases were searched to identify randomised controlled trials testing breathing techniques (techniques that aim to alter the respiratory pattern, excluding respiratory muscle training) in people with serious respiratory illness. The primary outcome was breathlessness and secondary outcomes were health-related quality of life and adverse events. Two authors independently screened for inclusion, evaluated risk of bias and extracted data.
RESULTS: 73 randomised controlled trials were included with 5479 participants, most with COPD or asthma. Breathing exercises (pursed lip and/or diaphragmatic breathing) reduced breathlessness measured by the modified Medical Research Council scale compared to usual care (mean difference (MD) -0.40 points, 95% CI -0.70- -0.11, eight studies, n=323), although the effect did not exceed the minimal important difference. Yoga breathing also improved modified Medical Research Council score compared to usual care (MD -1.05 points, 95% CI -2.45-0.35, three studies, n=175). Breathing techniques consistently improved health-related quality of life in people with COPD and asthma on multiple health-related quality of life measures in comparison to usual care, with effects that generally exceeded the minimal important difference. No adverse events related to breathing techniques were reported.
CONCLUSION: Breathing techniques may improve breathlessness, and consistently improve health-related quality of life, in people with serious respiratory illness. These findings support the use of breathing exercises in the care of people with serious respiratory illness.
OBJECTIVE: This study aimed to investigate the effect of Pilates exercise on the quality of life, functional capacity, cancer-related fatigue, depression and salivary cortisol of colorectal cancer survivors.
METHODS: This is a quasi-experimental study which was conducted at Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia (UKM), and Hospital Al-Sultan Abdullah, Universiti Teknologi MARA (UiTM), Malaysia. The intervention group performed Pilates exercises with a certified Pilates instructor for eight weeks via online streaming from the participants' homes. Meanwhile, the control group participants received the usual care as stipulated by their oncologists. The primary outcome was the quality of life. The secondary outcomes were functional capacity, cancer-related fatigue, depression and salivary cortisol. Data was collected at baseline and eight weeks after the exercise intervention. The effects of the intervention were analyzed using Repeated Measures Analysis of Covariance (ANCOVA) statistical test.
RESULT: Thirty-six (36) colorectal cancer survivors were allocated into either a Pilates exercise intervention group (N= 18) or a control group (N= 18). Over eight weeks, the Pilates exercise group revealed significant group x time interactions in terms of quality of life (p = 0.003), role functioning (p = 0.012), functional capacity (p = 0.048), and stool frequency (p = 0.021). However, only the stool frequency symptom (p = 0.008) remained significant after controlling for the confounders of age, gender and stage of cancer. No significant changes in cancer-related fatigue, depression and salivary cortisol levels between the groups were observed after the intervention.
CONCLUSION: Pilates exercise had positive impacts on role functioning, bowel function, and functional capacity among colorectal cancer survivors, ultimately contributing to an improvement in quality of life.
Children in this group received the same conventional treatment plus they were provided with solid community-prescribed AFO with a wearing schedule of 6-12 hours per day. Parents were given a detailed demonstration about how to use the AFO probably and watching for areas of skin overpressure. AFO needs to be worn with a smooth, long sock underneath with the child's heel is right down in the AFO with the ankle strap and/or shoe fastened firmly.
After obtaining parental consent, preterm neonates diagnosed with respiratory distress syndrome will be randomly administered a High dose of Intratracheal Alveofact (100 mg/kg) once without Budesonide. The clinical improvement of ventilatory settings, oxygen requirement, Assessment of Neutrophil Extracellular Trap (NET) formation, and Reactive Oxygen Species (ROS) will then be assessed before and 48 hours after treatment.
Regular physical activity has many benefits for overall health and well-being, and current public health guidelines recommend at least 150 minutes per week of moderate-to-vigorous intensity activity to attain these benefits. Despite the many benefits of regular activity, the majority of adults in the US fail to meet recommendations for regular physical activity. One potential explanation for suboptimal levels of physical activity is that exercise is often experienced as affectively unpleasant. Recent work has demonstrated that the more positive people feel during exercise, the more likely they are to engage in regular physical activity. Affective response to exercise is modulated by the intensity of the activity: at a vigorous intensity, affective response is almost uniformly negative and unpleasant, whereas at a moderate intensity, there is more inter-individual variability in affective response. Whether the intensity of the exercise is self-selected or imposed also influences the affective response to exercise, with self-selected intensities being experienced as more pleasant. Current recommendations for engaging in physical activity focus on the type of training intensities most likely to result in a negative affective response. The purpose of this pilot trial was to test the effects of an exercise prescription focused on the maintenance of positive affect during exercise. Investigators randomized participants to one of two exercise prescription conditions: (1) an affect-guided prescription focused on maintaining a positive affective response (intervention), and (2) a heart rate-guided prescription focused on maintaining a moderate intensity (control). Investigators tested the effects of these two exercise prescriptions on changes in subsequent physical activity after one week and one month among a sample of underactive adults. Investigators also tested whether the effect of the intervention was moderated by differences in cardiorespiratory fitness.
INTRODUCTION: Comprehensive and standardized colonoscopy reports are crucial in colorectal cancer prevention, monitoring, and research. This study investigates adherence to national and international guidelines by analyzing reporting practices among 21 endoscopists in 7 German centers, with a focus on polyp reporting.
METHODS: We identified and assessed German, European, American, and World Health Organization-provided statements to identify key elements in colonoscopy reporting. Board-certified gastroenterologists rated the relevance of each element and estimated their reporting frequency. Adherence to the identified report elements was evaluated for 874 polyps from 351 colonoscopy reports ranging from March 2021 to March 2022.
RESULTS: We identified numerous recommendations for colonoscopy reporting. We categorized the reasoning behind those recommendations into clinical relevance, justification, and quality control and research. Although all elements were considered relevant by the surveyed gastroenterologists, discrepancies were observed in the evaluated reports. Particularly diminutive polyps or attributes which are rarely abnormal (e.g., surface integrity) respectively rarely performed (e.g., injection) were sparsely documented. Furthermore, the white light morphology of polyps was inconsistently documented using either the Paris classification or free text. In summary, the analysis of 874 reported polyps revealed heterogeneous adherence to the recommendations, with reporting frequencies ranging from 3% to 89%.
CONCLUSION: The inhomogeneous report practices may result from implicit reporting practices and recommendations with varying clinical relevance. Future recommendations should clearly differentiate between clinical relevance and research and quality control or explanatory purposes. Additionally, the role of computer-assisted documentation should be further evaluated to increase report frequencies of non-pathological findings and diminutive polyps.
The present invention relates to the use of chlorine dioxide compositions for treating cancerous tumors. The present invention relates to compositions and methods for treating cancerous tumors, including naïve, metastatic and recurrent cancers. The compositions comprise chlorine dioxide in an effective amount, which is injected into the cancerous tumor at least once, and often at least several times over the course of treatment. The chlorine dioxide compositions are injected directly into the cancerous tumor and the resulting tumor is effectively eliminated from the patient or subject over a period of one to several days to a few weeks, often after a single injection, or multiple injections at one session into the tumor. Often, an initial injection or multiple injections at one session are sufficient to dissolve the cancerous tumor. Often the cancer is eliminated (as evidenced by no remission) in a period of no more than several days to about two-three months and does not recur.
Multiple anabolic deficiencies are common in chronic heart failure (CHF) and identify subgroups of patients with higher mortality. Apart from CHF, GH deficiency (GHD) per se increases cardiovascular mortality in the general population and low IGF-1 levels in the general population predict the development of ischemic heart disease and CHF. GHD modifies cardiac size and function, through a reduction in both myocardial growth and cardiac performance. The investigators therefore completed 2 studies aimed at evaluating the clinical status, neurohormonal parameters, exercise capacity, vascular reactivity, and left ventricular architecture and function in patients with GHD and CHF, at baseline and after 6 months of GH replacement therapy. They subsequently extended the observation period up to 48 months. At 6-months, GH replacement therapy improved clinical status and exercise capacity, as shown by a significant reduction of the Minnesota living with heart failure questionnaire score, increased peak oxygen consumption and exercise duration, and flow mediated vasodilation of the brachial artery. No major adverse events were reported in the patients receiving GH.

However, the encouraging results of these studies are limited by the lack of a double-blind, placebo-controlled design, insofar as the investigators performed a randomized controlled, single-blind study.
FIELD: medicine, gastroenterology, therapy. SUBSTANCE: method involves intramuscular administration of derinate (1.5% solution of DNA sodium salt in 0.1% solution of sodium chloride) in a dose 5.0 ml per 24 h, each other day. The total course of treatment is 3-5 injections. Method ensures to effect on reparative regeneration of stomach mucous tissue. EFFECT: enhanced effectiveness of treatment. 4 ex
The concept is put forward here that heat abstraction sensations, captured by topical application of a molecule, can be used to alleviate discomfort of non-keratinizng tissues. By synthesizing compounds and devising tests, a molecule name DAPA-2-5 was identified as having the selective desirable properties for achieving this purpose. DAPA-2-5 is a di-alkyl-phosphinoyl-alkane, and “DAPA-2-5” is 1-Di(sec-butyl)-phosphinoyl-pentane. DAPA-2-5 evokes a dynamic cooling sensation on non-keratinizing body surfaces (including, e.g., oropharyngeal, esophageal, and anogenital surfaces) which is not accompanied by stinging, irritation, or unpleasant tastes. Thus, it can be used to treat (e.g., suppress) sensory discomfort from non-keratinizing stratified epithelium (NKSE) selectively. This unusual selectivity, potency, and efficacy was also surprisingly exhibited in laboratory animal tests of inhibition of heat-induced edema, of eliciting skin irritation, and of inhibition of acid-induced swallowing. DAPA-2-5 is useful, for example, in the treatment of disorders (e.g., diseases) including sensory discomfort from non-keratinizng stratified epithelial (NKSE) tissue; upper aerodigestive tract discomfort; oropharyngeal discomfort; esophageal discomfort; throat irritation; cough; heartburn; chest pain; anogenital discomfort; or inflammation of non-keratinizng stratified epithelial (NKSE) tissue. The present discovery also pertains to pharmaceutical compositions comprising DAPA-2-5 and DAPA compositions, for example, in therapy and in differential diagnosis. A particularly favoured embodiment is 1-(Di-sec-butyl-phosphinoyl-pentane as an orally disintegrating tablet formulated with a mineral excipient called magnesium aluminosilicate.